Precision Medicine for L/GCMN and Melanoma 2
The primary objective is to evaluate the possibility of using minimally and non-invasive technologies (skin patch and breath analyzer) based on the detection of volatile organic compounds (VOCs) for the early identification of metastases. The secondary objective is to evaluate the usability of these technologies in the
| Condition(s) | Melanoma (Skin Cancer), Nevi and Melanomas, Congenital Melanocytic Nevus |
|---|---|
| Status | Recruiting |
| Study type | Observational |
| Summary | The primary objective is to evaluate the possibility of using minimally and non-invasive technologies (skin patch and breath analyzer) based on the detection of volatile organic compounds (VOCs) for the early identification of metastases. The secondary objective is to evaluate the usability of these technologies in the follow up of high-risk melanoma patients. |
| Who can participate | Inclusion Criteria: * Be over 18 years old * Have a histopathological confirmed melanoma diagnosis (stage II, III or IV AJCC) Exclusion Criteria: * Not signing the informed consent form * Present other cancers or chronic diseases (such as diabetes, asthma, etc.), which may affect the volatile organic compound profiles |
| Ages | 18 Years |
| Sex | All |
| Lead sponsor | Fundacion Clinic per a la Recerca Biomédica |
| Locations | Barcelona, Spain; Barcelona, Spain; Barcelona, Spain |
| Start date | 2025-01-01 |
| NCT ID | NCT06605443 |
| Official listing | https://clinicaltrials.gov/study/NCT06605443 |